{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.71","estimateComment":"IPTW HR were estimated using weighted Cox proportional hazard models and confidence intervals were estimated using robust error variances. Stabilized IPT weights truncated at the 99.5th percentile were used.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"=0.0011","paramType":"Hazard Ratio (HR)","paramValue":"0.52","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"3.42","upperLimit":"NA","value":"10.58"},{"groupId":"OG001","lowerLimit":"4.53","upperLimit":"7.26","value":"6.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"238"}],"units":"Participants"}],"description":"PFS: A) C1071003 Cohort A: time from date of first dose of elranatamab until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. Participants censored at loss to or end of follow-up. B) Flatiron Health Database: time from SOC to either date of progression or death due to any cause. Participants censored at loss to follow-up or end of study period. PD per IMWG criteria: increase of \\>=25% from lowest response value in any 1 or more of the criteria: SPEP with absolute increase \\>0.5 g/dL; 24-hour UPEP with absolute increase \\>200 mg/24 h; in participants without measurable serum and urine M-protein, absolute increase of \\>10 mg/dL in difference between involved and uninvolved FLC level; or absolute bone marrow plasma cell percentage \\>10%. Kaplan Meier method used for analysis. Retrospective data evaluated in this observational study for approximately 9 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eligible participants with TCR-MM, who were BCMA naïve, who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) Cohort A were included.","id":"OG000","title":"C1071003 Cohort A"},{"description":"Eligible participants with TCR-MM who initiated SOC treatment and were identified from Flatiron Health database in real world setting under routine clinical practice outside of clinical trials were included. This arm served as external control arm.","id":"OG001","title":"RWD: Flatiron Health Database"}],"paramType":"MEDIAN","populationDescription":"Eligible participants whose data was retrieved and was used in this retrospective cohort study. In this outcome measure, IPTW analysis was applied. IPTW eliminated the effect of confounding by observed baseline participant characteristics, improve covariate balance, and thereby obtained unbiased estimates of treatment effects.","reportingStatus":"POSTED","timeFrame":"C1071003: First dose to PD or death due to any cause or censoring whichever occurred first (max follow-up of 2.09Y); Flatiron Health Database: SOC to PD or death due to any cause or censoring whichever occurred first (max follow-up of 6.45Y)","title":"PFS: C1071003 Cohort A Versus Flatiron Health Database Using IPTW Analysis","type":"SECONDARY","unitOfMeasure":"Months"}